KDM7A and KDM1A inhibition suppresses tumour promoting pathways in prostate cancer

Molecular Oncology · Published 2026-03-23 · DOI 10.1002/1878-0261.70238

Free full text

Authors being retrieved — see the publisher record. https://doi.org/10.1002/1878-0261.70238

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Related articles

• Revisiting Mission‐Oriented Cancer Research to tackle the increasing burden of cancer in Europe–a policy perspective · Molecular Oncology · 2026 · Same journal
• Transcriptional profiling of circulating extracellular vesicles from prebiopsy prostate cancer patients · Molecular Oncology · 2026 · Same journal
• Longitudinal genome‐wide aneuploidy measurements in circulating cell‐free DNA to predict lack of benefit from pembrolizumab in patients with metastatic urothelial cancer · Molecular Oncology · 2026 · Same journal
• Interferon beta drives therapy resistance in a patient‐derived model of high‐grade serous ovarian cancer · Molecular Oncology · 2026 · Same journal
• Translating whole‐genome doubling into precision medicine in cancer · Molecular Oncology · 2026 · Same journal
• Stimulator of interferon genes agonist augmented antitumor immunity of osimertinib in Egfr ‐mutated lung cancer · Molecular Oncology · 2026 · Same journal
• NKCC1 : A key regulator of glioblastoma progression · Molecular Oncology · 2026 · Same journal
• EDNRB‐dependent endothelin signaling reduces proliferation and promotes proneural‐to‐mesenchymal transition in gliomas · Molecular Oncology · 2026 · Same journal
• Liquid biopsy‐based diagnostic evaluation of hypermethylated CpG sites for ovarian cancer diagnosis · Molecular Oncology · 2026 · Same journal
• Single‐cell DNA methylation profiling: Technologies, computation, and applications in precision oncology · Molecular Oncology · 2026 · Same journal